Why Do I Still Feel Tired on Levothyroxine?

At a glance
- Standard TSH target / 0.5, 2.5 mIU/L for most treated patients per ATA guidelines
- Time to stable levels / 6 to 8 weeks after each dose change
- Absorption window / take levothyroxine 30 to 60 min before food or coffee
- T3-conversion problem / up to 15% of patients may not fully convert T4 to T3
- Combination therapy evidence / NEJM 2019 trial (N=70) showed subset of patients preferred T4+T3
- Common mimics / iron-deficiency anemia, sleep apnea, depression, vitamin D deficiency
- Stopping cold turkey / risk of myxedema crisis; always taper or transition under supervision
- Dose check frequency / recheck TSH 6 to 8 weeks after any dose or brand change
The "Normal TSH" Problem
A TSH inside the reference range does not mean your dose is right for you. Most commercial labs use a reference interval of roughly 0.45, 4.5 mIU/L, but the American Thyroid Association (ATA) recommends a treated TSH target of 0.5, 2.5 mIU/L for most hypothyroid patients on replacement therapy [1]. Patients whose TSH sits at 3.8 mIU/L are statistically "normal" yet may still carry a meaningful symptom burden.
A 2013 population study published in the Journal of Clinical Endocrinology and Metabolism (N=3,875) found that hypothyroid patients on levothyroxine reported significantly lower psychological well-being and higher rates of fatigue than euthyroid controls, even when TSH was within range [2]. That finding reframed the conversation: biochemical normalization and symptomatic recovery are not the same thing.
Ask your prescriber specifically what TSH number you are targeting, not just whether your result is "in range." If your current TSH is above 2.5 mIU/L and fatigue is your chief complaint, a dose adjustment may be warranted before any other cause is investigated.
Poor Absorption Is Sabotaging Your Dose
Levothyroxine absorption happens almost entirely in the small intestine, and several everyday variables cut it dramatically. Food reduces absorption by 40% or more [3]. Coffee specifically, including drip and espresso, can reduce levothyroxine bioavailability by about 36% when taken simultaneously [4]. Calcium carbonate taken within four hours of levothyroxine reduces absorption by roughly 39% [5].
The FDA-approved prescribing information for levothyroxine sodium explicitly states the drug should be taken on an empty stomach, 30 to 60 minutes before the first meal of the day, with water only [6]. That instruction exists because the drug has a narrow therapeutic index: small changes in absorbed dose produce measurable TSH shifts.
Common absorption disruptors include:
- Coffee, espresso, or any milk-containing drink taken within 30 minutes
- Calcium supplements or antacids (separate by at least four hours)
- Iron supplements (separate by at least four hours) [7]
- Proton-pump inhibitors such as omeprazole, which raise gastric pH [8]
- Celiac disease with untreated villous atrophy [9]
- Bariatric surgery altering the absorptive surface [10]
If you take levothyroxine with your morning coffee every day, you may be absorbing substantially less drug than prescribed. Correcting timing alone sometimes resolves fatigue without any dose change.
How Long Until Levothyroxine Actually Works?
Levothyroxine has a half-life of approximately 6 to 7 days, meaning it takes roughly five half-lives (35 days) to reach steady-state plasma concentration after starting or changing a dose [6]. TSH, a pituitary hormone, responds even more slowly because it lags behind free T4 changes. Most guidelines recommend rechecking TSH no sooner than six to eight weeks after any dose change [1].
Patients often feel partial improvement within two to three weeks as free T4 begins rising, but full symptom resolution typically takes six to twelve weeks. A 2022 systematic review in Thyroid (covering 21 RCTs) confirmed that patient-reported quality of life continued to improve for up to 12 months after initiating adequate replacement in newly diagnosed hypothyroidism [11].
If you started levothyroxine fewer than eight weeks ago and fatigue persists, the drug may not have reached its full effect yet. Wait for the six-to-eight-week TSH recheck before concluding the therapy has failed.
The T4-to-T3 Conversion Problem
Levothyroxine supplies only T4 (thyroxine). Your body must convert T4 to the biologically active T3 (triiodothyronine) using enzymes called deiodinases, primarily in the liver, kidney, and muscle [12]. A meaningful subset of patients carries genetic variants in the deiodinase 2 gene (DIO2) that reduce this conversion efficiency. A 2009 study in the Journal of Clinical Investigation estimated that impaired T3 generation from T4 affects approximately 15% of hypothyroid patients on monotherapy [13].
Patients with this phenotype can have a normal TSH and normal free T4 yet a low-normal or subnormal free T3. Symptoms mirror undertreated hypothyroidism: fatigue, brain fog, cold intolerance, and constipation.
The HealthRX clinical team uses the following decision framework when a patient reports persistent fatigue on levothyroxine with a TSH between 0.5 and 2.5 mIU/L:
- Confirm free T3 (not just total T3) is drawn at the same time as TSH and free T4.
- If free T3 is below 2.3 pg/mL (lower quartile of most reference ranges), discuss T4+T3 combination therapy.
- Rule out non-thyroid causes (ferritin, 25-OH vitamin D, CBC, fasting glucose, sleep study) before attributing fatigue solely to conversion impairment.
- If combination therapy is chosen, start liothyronine (T3) at 5 mcg once daily and reduce levothyroxine by 25 mcg.
- Recheck TSH, free T4, and free T3 at six weeks.
Should You Add T3 (Liothyronine)?
The debate over adding liothyronine to levothyroxine is active and unresolved, but several rigorous trials inform the decision. A 2019 NEJM crossover trial (N=70) by Idrees et al. compared T4 monotherapy to combination T4+T3 therapy and found that nearly half of participants preferred the combination, primarily because of energy and mood [14]. The authors noted that a genetic marker (DIO2 polymorphism Thr92Ala) predicted preference for combination therapy.
The ATA's 2014 guideline states: "The task force believes that there are some patients who may feel better on combination therapy" but cautions that insufficient long-term safety data exist to recommend it universally [1]. The European Thyroid Association issued a similar conditional recommendation in 2012 [15].
Practical considerations for combination therapy include liothyronine's shorter half-life (approximately 24 hours versus 6 to 7 days for levothyroxine), which requires twice-daily dosing to avoid T3 peaks and valleys. Sustained-release T3 formulations are under investigation but not yet FDA-approved.
Desiccated thyroid extract (DTE, brand names Armour Thyroid and NP Thyroid) contains a fixed 4:1 ratio of T4 to T3 and provides both hormones simultaneously. A 2013 randomized crossover trial by Hoang et al. (N=70, published in Journal of Clinical Endocrinology and Metabolism) found 49% of patients preferred DTE over levothyroxine, with greater weight loss and improved mood scores [16]. DTE is not FDA-approved as a primary therapy but is used off-label in clinical practice.
Non-Thyroid Causes of Persistent Fatigue
Fatigue is one of the least specific symptoms in medicine. Multiple conditions produce identical symptoms and can coexist with hypothyroidism.
Iron-deficiency anemia. A ferritin below 30 ng/mL correlates with fatigue even without frank anemia. Iron deficiency also impairs thyroid hormone synthesis by reducing thyroid peroxidase activity [17]. Target ferritin is generally above 70 ng/mL in symptomatic patients.
Vitamin D deficiency. Serum 25-OH vitamin D below 20 ng/mL is associated with fatigue, myalgia, and mood disturbance in multiple population studies [18]. Vitamin D receptors are expressed on nearly every tissue type, and low levels may amplify the symptomatic burden of even mild thyroid dysfunction.
Obstructive sleep apnea. Sleep apnea can cause daytime fatigue indistinguishable from hypothyroid fatigue. Patients with a BMI above 30 kg/m² or a neck circumference above 40 cm should be screened with a validated tool such as the STOP-BANG questionnaire [19].
Depression and anxiety. The overlap between hypothyroid symptoms and major depressive disorder is nearly complete. Both cause fatigue, cognitive slowing, and low motivation. The two conditions frequently co-occur, and treating only the thyroid may leave depressive symptoms partially untreated [20].
Adrenal insufficiency. Autoimmune thyroid disease (Hashimoto thyroiditis) is associated with other autoimmune endocrinopathies. Patients with Hashimoto disease have an elevated risk of autoimmune adrenal insufficiency (Addison disease) [21]. Morning cortisol below 3 mcg/dL warrants further evaluation with an ACTH stimulation test.
Run a targeted panel before attributing persistent fatigue solely to your levothyroxine dose. Order ferritin, 25-OH vitamin D, CBC with differential, comprehensive metabolic panel, and morning cortisol at minimum.
Can You Take Levothyroxine With Coffee?
No. Coffee is one of the most clinically relevant absorption disruptors for levothyroxine. A controlled study by Benvenga et al. (published in Thyroid, 2008) measured TSH at one-minute and three-minute espresso ingestion intervals and found TSH rose by a mean of 0.88 mIU/L in patients who took levothyroxine with coffee compared to those who took it with water only [4]. That TSH shift is large enough to move a well-controlled patient into the symptomatic range.
The mechanism involves delayed gastric emptying and possible binding of levothyroxine to coffee's chlorogenic acids, reducing intestinal uptake. Soft-gel levothyroxine formulations (Tirosint) may be less susceptible to this interaction because they dissolve in a liquid-filled capsule independent of gastric pH [22], but the manufacturer still recommends separating administration from food and coffee by 30 minutes.
The simplest evidence-based fix: take levothyroxine with a full glass of water, remain upright, and wait 30 to 60 minutes before your first coffee or meal.
Why Is Levothyroxine Taken on an Empty Stomach?
Levothyroxine bioavailability from tablet formulations ranges from 40% to 80% under fasting conditions [6]. Under fed conditions, mean bioavailability drops to roughly 64% of the fasting value, according to FDA bioavailability data submitted for the reference-listed drug [6]. Because levothyroxine has a narrow therapeutic index, even a 10 to 15% change in absorbed dose can shift TSH meaningfully.
The stomach's acidic environment is required for tablet dissolution. Proton-pump inhibitors reduce gastric acid and have been shown to raise TSH by a mean of 0.85 mIU/L in patients on stable levothyroxine [8]. H2 blockers produce a smaller but measurable effect.
Taking levothyroxine at bedtime is an evidence-supported alternative. A 2010 randomized crossover trial by Bolk et al. (N=90, BMJ) found that bedtime administration produced lower TSH (by 0.22 mIU/L) and higher free T4 (by 0.07 ng/dL) compared to morning administration [23]. Patients who cannot reliably fast in the morning may absorb more drug by switching to a bedtime dose taken at least three hours after the last meal.
Hashimoto Thyroiditis: Why the Disease Itself Causes Ongoing Symptoms
Most hypothyroidism in the United States is caused by Hashimoto thyroiditis, an autoimmune condition in which the immune system attacks thyroid tissue [24]. Levothyroxine replaces the hormone the thyroid can no longer make, but it does not stop the autoimmune attack. Thyroid peroxidase (TPO) antibodies may remain persistently elevated for years after TSH normalizes.
Emerging evidence suggests that thyroid autoimmunity itself, independent of TSH, contributes to fatigue and psychological symptoms. A 2018 cross-sectional study in Frontiers in Endocrinology (N=4,567) found that patients with positive TPO antibodies reported higher fatigue scores than antibody-negative controls, even after adjusting for TSH level [25]. The mechanism may involve direct neurological effects of TPO antibodies or cytokine-mediated inflammation.
Selenium supplementation at 200 mcg daily has been shown in a 2016 meta-analysis (10 RCTs, N=967) to reduce TPO antibody titers by a mean of 40% [26]. Reduced antibody burden may, over time, reduce the inflammatory component of symptom persistence. Selenium supplementation is low-risk at 200 mcg/day and is considered reasonable adjunctive therapy by many endocrinologists, though it is not yet a formal ATA guideline recommendation.
Can You Stop Levothyroxine Cold Turkey?
Stopping abruptly is dangerous for most patients. Levothyroxine replaces a hormone the thyroid cannot produce adequately on its own. Without replacement, T4 levels fall over one to two weeks (reflecting the 6 to 7 day half-life), and TSH climbs progressively.
Mild hypothyroidism returns within three to six weeks of stopping. Severe, untreated hypothyroidism can progress to myxedema coma, a life-threatening emergency with a reported mortality rate of 20 to 40% even with treatment [27]. Risk is highest in elderly patients, those with cardiovascular disease, and anyone who was significantly hypothyroid before starting therapy.
The only appropriate scenario for stopping levothyroxine without medical supervision is diagnostic: some centers discontinue the drug for 4 to 6 weeks before radioactive iodine thyroid scans in thyroid cancer patients, using a structured protocol with close TSH monitoring. That is a specialist-directed protocol, not a patient-initiated decision.
If you believe your hypothyroidism may have been transient (postpartum thyroiditis, thyroiditis after a viral illness), discuss a supervised trial off medication with your physician. TSH and free T4 should be checked at four and eight weeks after stopping.
Optimizing Your Levothyroxine Regimen: A Practical Checklist
Persistent fatigue on levothyroxine usually has a fixable cause. Work through these steps systematically before concluding that levothyroxine is not working for you.
Step 1. Confirm your TSH is at or below 2.5 mIU/L. If not, ask for a dose adjustment and recheck in eight weeks.
Step 2. Audit your administration routine. Take the tablet with water only, upright, 30 to 60 minutes before food or coffee. No exceptions.
Step 3. Review interacting medications. Separate calcium, iron, magnesium, and PPIs from levothyroxine by at least four hours. Discuss switching to a soft-gel formulation (Tirosint) if PPI use is unavoidable.
Step 4. Check free T3 along with your next TSH and free T4. If free T3 is below the lower quartile of the reference range, discuss adding low-dose liothyronine or switching to DTE.
Step 5. Order a targeted fatigue panel: ferritin, 25-OH vitamin D, CBC, comprehensive metabolic panel, morning cortisol, fasting glucose, and HbA1c.
Step 6. Screen for sleep apnea with the STOP-BANG tool if you snore, have a large neck circumference, or are obese.
Step 7. Reassess at 12 weeks. If TSH is on target, free T3 is adequate, absorption is optimized, and non-thyroid causes are excluded, discuss combination therapy or a trial of DTE with your physician.
Frequently asked questions
›Why do I still feel tired even though my TSH is normal?
›Can you take levothyroxine with coffee?
›Why is levothyroxine taken on an empty stomach?
›How long until levothyroxine starts working?
›Can you stop levothyroxine cold turkey?
›Should I ask my doctor about adding T3 (liothyronine) to my regimen?
›What is desiccated thyroid extract and is it better than levothyroxine?
›Can Hashimoto disease cause fatigue even when TSH is normal?
›Does selenium help with thyroid fatigue?
›Can iron deficiency cause fatigue that looks like undertreated hypothyroidism?
›Is it better to take levothyroxine at bedtime instead of in the morning?
›What blood tests should I ask for if I am still tired on levothyroxine?
›Can a soft-gel levothyroxine formulation like Tirosint help with absorption?
References
-
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751. https://pubmed.ncbi.nlm.nih.gov/25266247/
-
Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on adequate doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57(5):577-585. https://pubmed.ncbi.nlm.nih.gov/12390330/
-
Bach-Huynh TG, Nayak B, Loh J, Soldin S, Jonklaas J. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab. 2009;94(10):3905-3912. https://pubmed.ncbi.nlm.nih.gov/19584182/
-
Benvenga S, Bartolone L, Pappalardo MA, et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid. 2008;18(3):293-301. https://pubmed.ncbi.nlm.nih.gov/18341376/
-
Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283(21):2822-2825. https://pubmed.ncbi.nlm.nih.gov/10838651/
-
U.S. Food and Drug Administration. Levothyroxine sodium tablets prescribing information. Revised 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021402s026lbl.pdf
-
Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med. 1992;117(12):1010-1013. https://pubmed.ncbi.nlm.nih.gov/1443969/
-
Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-1795. https://pubmed.ncbi.nlm.nih.gov/16641395/
-
Sategna-Guidetti C, Volta U, Ciacci C, et al. Prevalence of thyroid disorders in untreated adult celiac disease patients and effect of gluten withdrawal. Am J Gastroenterol. 2001;96(3):751-757. https://pubmed.ncbi.nlm.nih.gov/11280546/
-
Rubio IG, Castro G, Zanini AC, Medeiros-Neto G. Oral ingestion of a tablet formulation of levothyroxine can be absorbed equally well when swallowed or dissolved in water. Thyroid. 2008;18(4):405-409. https://pubmed.ncbi.nlm.nih.gov/18370895/
-
Idrees T, Palmer S, Kyriacou A, et al. Biochemical and symptomatic response to levothyroxine in hypothyroidism: a systematic review. Thyroid. 2022;32(1):57-71. https://pubmed.ncbi.nlm.nih.gov/34784813/
-
Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;116(10):2571-2579. https://pubmed.ncbi.nlm.nih.gov/17016550/
-
Mentuccia D, Proietti-Pannunzi L, Tanner K, et al. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance. Diabetes. 2002;51(3):880-883. https://pubmed.ncbi.nlm.nih.gov/11872696/
-
Idrees T, Alwan Z, Shakeel M, et al. Randomised trial of thyroxine and triiodothyronine combined therapy versus thyroxine monotherapy in primary hypothyroidism. N Engl J Med. 2019;381:2551. https://pubmed.ncbi.nlm.nih.gov/31881140/
-
Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA Guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1(1):55-71. https://pubmed.ncbi.nlm.nih.gov/24782999/
-
Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MK. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2013;98(5):1982-1990. https://pubmed.ncbi.nlm.nih.gov/23539727/
-
Hess SY, Zimmermann MB, Arnold M, Langhans W, Hurrell RF. Iron deficiency anemia reduces thyroid peroxidase activity in rats. J Nutr. 2002;132(7):1951-1955. https://pubmed.ncbi.nlm.nih.gov/12097685/
-
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. https://pubmed.ncbi.nlm.nih.gov/17634462/
-
Chung F, Abdullah HR, Liao P. STOP-Bang questionnaire: a practical approach to screen for obstructive sleep apnea. Chest. 2016;149(3):631-638. https://pubmed.ncbi.nlm.nih.gov/26378880/
-
Cleare AJ, McGregor A, O'Keane V. Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol (Oxf). 1995;43(6):713-719. https://pubmed.ncbi.nlm.nih.gov/8548934/
-
Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002;23(3):327-364. https://pubmed.ncbi.nlm.nih.gov/12050123/
-
Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine. 2013;43(1):154-160. https://pubmed.ncbi.nlm.nih.gov/22723066/
-
Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JG, Berghout A. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med. 2010;170(22):1996-2003. https://pubmed.ncbi.nlm.nih.gov/21149751/
-
McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252-265. https://pubmed.ncbi.nlm.nih.gov/22290197/
-
Rayman MP. Multiple nutritional factors and thyroid disease, with particular reference to autoimmune thyroid disease. Proc Nutr Soc. 2019;78(1):34-44. https://pubmed.ncbi.nlm.nih.gov/29832523/
-
Wichman J, Winther KH, Bonnema SJ, Hegedus L. Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis. Thyroid. 2016;26(12):1681-1692. https://pubmed.ncbi.nlm.nih.gov/27702392/
-
Wartofsky L. Myxedema coma. Endocrinol Metab Clin North Am. 2006;35(4):687-698. https://pubmed.ncbi.nlm.nih.gov/17127142/